Table 2. Characteristics of responding patients.
| Patient no. | 6 | 8 | 12 |
|---|---|---|---|
| Sex | Male | Female | Male |
| Age | 46 | 55 | 44 |
| Prior nephrectomy | Yes | Yes | Yes |
| Histology | Mixed clear cell and granular | Granular | Granular |
| Prior systemic therapy | Atzpodien regimena | 1. 5-FU + IL-2 | Atzpodien regimena |
| 2. IL-2 + IFN | |||
| Time since diagnosis of metastases (months) | 12 | 13 | 7 |
| Metastatic sites | Lung | Lung, lymph nodes, bone | Lung, liver |
| Performance status | 0 | 1 | 1 |
| Number of poor prognostic factors | 1 | 0 | 1 |
| Duration of response (months) | 5.6 | 5.8 | 18.8b |
| Time to disease progression (months) | 7.9 | 7.6 | 20.8b |
| Post-trial therapy | BAY 43-9006c | Provera | None |
| Overall survival (months) | 21.5d | 9.9 | 20.8d |
a
IL-2, IFN-alpha and 5-FU (Atzpodien et al, 2001).
b
Remains free of disease progression on follow-up.
c
Phase II trial of a B-raf kinase inhibitor.
d
Remains alive on follow-up.